KalVista Pharmaceuticals, Inc. (KALV) is a biopharmaceutical organization that focuses on the research, development, and commercialization of innovative treatments for patients living with debilitating diseases that have significant unmet medical need.
Based in Cambridge, Massachusetts, and Salisbury, United Kingdom, the company was founded in 2011. It positions itself at the overlapping interface of drug discovery and clinical sciences, aiming to generate therapies that can effectively help patients around the world.
The primary focus of KalVista Pharmaceuticals is on the development of therapies for hereditary angioedema (HAE) and diabetic macular edema (DME), both of which are serious conditions that can greatly impact the quality of life of those affected. KalVista's portfolio includes a multiple phase clinical development program focused on the treatment of HAE, and they are also developing a new treatment for DME.
KalVista's approach to HAE centers around the inhibition of plasma kallikrein, a human enzyme that mediates inflammation in the body. They are developing novel, orally delivered drug candidates that aim to stop the production of this enzyme, thereby reducing the incidence of HAE attacks.
For DME, a leading cause of adult visual loss in developed countries, KalVista has advanced an investigational new drug application. The condition is often linked to diabetes, a disease that affects millions of individuals worldwide. By developing treatments for DME, KalVista aims to address a significant unmet need and contribute to improving global public health.
KalVista Pharmaceuticals, Inc. operates with a clear vision: to leverage its deep understanding of plasma kallikrein biology and structure-guided drug design approach to deliver transformative therapies to patients. Despite the inherent challenges of pharmaceutical R&D, the company maintains a robust pipeline of innovative drug candidates and continues to make strides in advancing their clinical development programs.
The company is publicly traded and is listed on the NASDAQ stock exchange under the ticker symbol KALV. Since its inception, KalVista Pharmaceuticals, Inc. has stood out as a dedicated player in the pharmaceutical industry, committed to changing the lives of individuals living with diseases that currently have limited treatment options. Through its innovative research and clinical development strategies in the face of challenges and uncertainties, KalVista continues to strive towards their ultimate goal - to bring much needed and effective treatments to patients around the world.